J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $46
J.P. Morgan has reiterated its Buy rating on Olema Pharmaceuticals (OLMA.US) and maintained a target price of $46. This continued positive outlook from the financial institution suggests confidence in the company's future performance. The maintained target price indicates that J.P. Morgan analysts believe the stock has significant upside potential from its current trading levels.
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Announces Target Price $46
J.P. Morgan has reiterated its Buy rating on Olema Pharmaceuticals (OLMA.US) and set a price target of $46. This indicates a positive outlook from the firm regarding the company's future performance.
Form 8K Olema Pharmaceuticals Inc For: 13 August By Investing.com
This article from Investing.com reports on an SEC Form 8-K filing by Olema Pharmaceuticals Inc. for August 13th. The content is brief, primarily serving as an announcement of the filing rather than providing detailed analysis. The article includes standard financial market data and popular news links, but the core information is the Form 8-K disclosure.
Form 8K Olema Pharmaceuticals Inc For: 13 August By Investing.com
This article announces the filing of a Form 8K by Olema Pharmaceuticals Inc. on August 13. It includes the stock symbol OLMA and indicates a slight negative change in its price. The content provides a general news format from Investing.com with market data and related articles.
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
Olema Pharmaceuticals, Inc. (Olema Oncology) has appointed Jason O’Byrne, MBA, as its new Chief Financial Officer. O'Byrne brings over two decades of finance and operations leadership from high-growth biotechnology and pharmaceutical organizations, including roles at Vir Biotechnology, Caribou Biosciences, Audentes Therapeutics, and Genentech/Roche. His appointment comes at a crucial time as Olema approaches pivotal data from OPERA-01 and prepares for a potential first commercial launch, aiming to transform into a fully integrated oncology company.
Olema Oncology’s New CFO Brings More Than Two Decades in Biotech
Olema Oncology (Nasdaq: OLMA) has appointed Jason O’Byrne as its new Chief Financial Officer, bringing over two decades of finance leadership experience in the biotech and pharmaceutical sectors. This appointment comes as the company approaches pivotal data from its OPERA-01 study and prepares for its first potential commercial launch. O’Byrne's extensive background in capital markets, M&A integration, and financial operations is expected to support Olema's transformation into a fully integrated oncology company.
Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027
Olema Pharmaceuticals' stock fell by 12.90% after the company announced that pivotal breast cancer data for its Phase 3 OPERA-01 trial would be delayed until the first quarter of 2027. Despite this setback, the company presented initial Phase 1 data for OP-3136, showing its continued development in women's cancer therapies. Analysts maintain a "Buy" rating with an average price forecast of $43.00, though some have lowered their individual forecasts.
Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027
Olema Pharmaceuticals' stock fell after announcing that top-line data for its pivotal Phase 3 OPERA-01 trial for breast cancer is now expected in Q1 2027, a delay from previous expectations. The company also reported a net loss of $63.2 million for Q2 2026, an increase from the previous year, attributed to higher spending on clinical development. Despite a "Buy" consensus from analysts, the stock is showing bearish technical indicators.
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
Olema Oncology reported its financial and operating results for the second quarter ended June 30, 2026, highlighting the completion of enrollment in its pivotal Phase 3 OPERA-01 trial for palazestrant, with top-line data expected in Q1 2027. The company also presented initial Phase 1 clinical data for OP-3136, showing anti-tumor activity, and announced a collaboration with Bayer to evaluate OP-3136 in metastatic castration-resistant prostate cancer. Olema ended the quarter with $461.1 million in cash, cash equivalents, and marketable securities, while reporting a net loss of $63.2 million, an increase from the prior year, primarily due to higher R&D and G&A expenses supporting late-stage clinical trials.
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Lowered to $59.00 at Citigroup
Citigroup has lowered its price target for Olema Pharmaceuticals (NASDAQ:OLMA) to $59.00 but maintained a "buy" rating, indicating a significant potential upside. This adjustment comes as the company reported a larger-than-expected quarterly loss of $0.61 per share. Olema Pharmaceuticals is a clinical-stage biotech focusing on treatments for women's cancers, with institutional investors holding a substantial stake in the company.
TD Cowen Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating
TD Cowen analyst Tyler Van Buren has reiterated a Buy rating on Olema Pharmaceuticals (OLMA.US). Van Buren has a 63.4% success rate and an average return of 38.8% over the past year, according to TipRanks data. The article emphasizes that this information is for informational purposes only and not an investment recommendation.
Olema Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $39.9, Implies 234% Upside
Olema Pharmaceuticals, Inc.'s average 12-month price target has been adjusted to $39.9, down from $40.7, according to estimates from 10 analysts. This new target suggests a potential upside of approximately 234% based on the August 10 closing price. The consensus rating from 11 analysts remains a "Buy" with no "Holds" or "Sells."
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Down on Disappointing Earnings
Olema Pharmaceuticals (NASDAQ:OLMA) gapped down after reporting Q2 EPS of $(0.61), missing analyst estimates. Despite the disappointing earnings, analyst sentiment remains largely positive with a "Moderate Buy" consensus rating and a $43.90 target price. Institutional investors hold a significant portion of the stock, while insider selling by Director Cyrus Harmon was noted.
Olema Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $40.1, Implies 236% Upside
Olema Pharmaceuticals, Inc. (OLMA) has seen its average 12-month price target adjusted to $40.1 by analysts, down from $40.7, implying a 236% potential upside from its current closing price. The consensus rating from 11 analysts remains a "Buy," with no "Hold" or "Sell" recommendations.
Olema Pharmaceuticals falls 6% on second quarter EPS miss
Olema Pharmaceuticals (NASDAQ:OLMA) reported a second-quarter loss of $0.61 per share, missing analyst estimates by $0.06, leading to a 5.8% stock decline. The company's net loss increased to $63.2 million due to higher spending on clinical development for breast cancer therapies palazestrant and OP-3136. Olema completed enrollment for its pivotal Phase 3 OPERA-01 trial, with top-line data expected in Q1 2027, and announced a collaboration with Bayer for OP-3136 in prostate cancer.
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
Olema Oncology announced its financial and operating results for the second quarter of 2026, highlighting the completion of enrollment in its pivotal Phase 3 OPERA-01 trial with top-line data expected in Q1 2027. The company also reported initial Phase 1 clinical data for OP-3136, showing anti-tumor activity and good tolerability, and a new collaboration with Bayer. Olema ended the quarter with $461.1 million in cash, cash equivalents, and marketable securities, with a net loss of $63.2 million due to increased R&D and G&A expenses for advancing clinical trials.
Olema Pharmaceuticals Q2 Loss Widens
NULL
Olema Pharmaceuticals Q2 Results: EPS misses estimates, losses widen
Olema Pharmaceuticals reported a Q2 EPS of $(0.61), missing the analyst consensus of $(0.55) by 10.91%. This represents a 19.61% increase in losses year-over-year from $(0.51), indicating persistent profitability challenges. The company's financial trajectory suggests a disconnect between market expectations and its current performance, with the reasons for widening losses remaining unclear without further revenue or margin data.
Earnings Flash (OLMA) Olema Pharmaceuticals Posts Q2 Loss per Share $0.61, vs. FactSet Est of $0.55 Loss
Olema Pharmaceuticals (OLMA) reported a Q2 loss per share of $0.61, which is wider than the FactSet estimated loss of $0.55 per share. The company is a clinical-stage biopharmaceutical company focused on breast cancer treatments. The article also mentions recent news regarding their clinical trial collaborations and inclusion in Russell indices.
Olema Pharmaceuticals falls 6% on second quarter EPS miss
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) reported a wider-than-expected second-quarter loss of $0.61 per share, missing analyst estimates. This news led to a 5.8% drop in its stock during after-hours trading. The increased net loss of $63.2 million was attributed to higher spending on clinical development and research activities for its breast cancer therapies, palazestrant and OP-3136.
Olema Pharmaceuticals (NASDAQ:OLMA) Releases Earnings Results, Misses Estimates By $0.08 EPS
Olema Pharmaceuticals (NASDAQ:OLMA) reported a quarterly loss of $0.61 per share, missing analysts' consensus estimate by $0.08. The company's stock traded down to $11.94, with a market capitalization of $1.04 billion. Despite missing estimates, Wall Street analysts maintain a "Moderate Buy" consensus rating with an average price target of $44.10.
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
Olema Oncology reported its financial and operating results for the second quarter ended June 30, 2026, highlighting the completion of enrollment in the pivotal Phase 3 OPERA-01 trial with top-line data expected in Q1 2027. The company also presented initial Phase 1 clinical data for OP-3136, showing it was well-tolerated with anti-tumor activity, and announced a collaboration with Bayer to evaluate OP-3136 in metastatic castration-resistant prostate cancer. Olema ended the quarter with $461.1 million in cash and reported a net loss of $63.2 million.
Olema Pharmaceuticals Q2 Loss Widens
Olema Pharmaceuticals (OLMA) reported a widening net loss of $0.61 per diluted share for the second quarter. The full details of this report are available to subscribers of Yahoo Finance Gold or other premium plans.
Olema Pharmaceuticals earnings up next ahead of key trial data
Olema Pharmaceuticals is set to report its second-quarter results, with analysts expecting wider losses as the clinical-stage biotech continues to advance its breast cancer pipeline. Investors are keenly awaiting top-line data from its Phase 3 OPERA-01 trial, expected this fall, which will be crucial for validating its lead drug palazestrant. The company also announced a collaboration with Bayer for its OP-3136 candidate, expanding its potential beyond breast cancer.
Dimensional Fund Advisors LP Acquires 123,790 Shares of Olema Pharmaceuticals, Inc. $OLMA
Dimensional Fund Advisors LP increased its stake in Olema Pharmaceuticals (NASDAQ:OLMA) by 12.9%, acquiring an additional 123,790 shares to bring its total holding to 1.08 million shares, valued at $16.1 million. Institutional ownership of OLMA remains high at 91.78%, with several other firms also initiating or expanding positions. Analysts generally rate OLMA as a "Moderate Buy" with an average price target of $44.10, despite the stock trading around $12.05 and the company currently being unprofitable.
FMR LLC, Abigail Johnson disclose 13.8% Olema Pharmaceuticals (OLMA) ownership
FMR LLC and Abigail P. Johnson have disclosed a 13.8% beneficial ownership stake in Olema Pharmaceuticals Inc. (OLMA) through an Amendment No. 2 to a Schedule 13G filing. This represents 12,075,061.72 shares as of June 30, 2026. FMR LLC holds sole voting power over 12,074,535 shares and both FMR LLC and Abigail Johnson hold sole dispositive power over 12,075,061.72 shares.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (Olema Oncology) announced that it granted stock options to seven new employees to purchase an aggregate of 254,540 shares of the Company's common stock. These grants, effective August 3, 2026, were made under Olema's 2022 Inducement Plan as an inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options have a 10-year term, an exercise price of $11.28 per share, and vest over four years.
Have Olema Pharmaceuticals Insiders Been Selling Stock?
Olema Pharmaceuticals has seen recent insider selling, including a notable divestment by an Independent Director and a larger sale by the Chief Medical Officer last year. While the CMO's sale was at a higher price than current stock, overall insider ownership is modest at 2.7%, and there have been no insider purchases in the last year, leading to caution regarding the stock.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced that it granted stock options to seven new employees to purchase an aggregate of 254,540 shares of its common stock. These grants were made under the Company's 2022 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years, have a 10-year term, and an exercise price of $11.28 per share.
Seven New Hires Get Olema Stock Options at $11.28 a Share
Olema Oncology has granted stock options to seven new employees, totaling 254,540 shares, effective August 3, 2026. These inducement grants, approved under Olema's 2022 Inducement Plan and in compliance with Nasdaq Listing Rule 5635(c)(4), have an exercise price of $11.28 per share and a 10-year term. The options will vest over four years, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments, subject to continued employment.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. announced the grant of stock options to seven new employees to purchase 254,540 shares of common stock. These grants, effective August 3, 2026, were approved by the Compensation Committee under the Company's 2022 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The options vest over four years, have a 10-year term, and an exercise price of $11.28 per share.
Olema Pharmaceuticals (OLMA) Expected to Release Quarterly Earnings on Monday
Olema Pharmaceuticals (OLMA) is scheduled to release its Q2 2026 earnings before market open on Monday, August 10th, with analysts anticipating a loss of $0.53 per share. The company's stock opened at $11.18, down 2.4%, and currently holds a "Moderate Buy" rating with an average analyst price target of $44.10, despite some recent downgrades. Institutional investors hold a significant 91.78% stake in the company, which is advancing its lead therapy candidate, OP-1250, for breast cancer into Phase 3 trials.
Defilade Capital Management L.P. Acquires 269,902 Shares of Olema Pharmaceuticals, Inc. $OLMA
Defilade Capital Management L.P. has increased its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 21.9%, purchasing an additional 269,902 shares to bring its total to 1.50 million shares valued at approximately $22.4 million. This acquisition makes Olema Pharmaceuticals the 14th largest position in Defilade Capital Management's holdings. Despite some downgrades, analysts generally maintain a "Moderate Buy" rating with an average price target of $44.10 for the clinical-stage biotechnology company, which recently reported a quarterly loss of $0.52 per share, in line with estimates.
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) has received a consensus "Moderate Buy" recommendation from fourteen brokerages, with an average 12-month target price of $44.10. Recent analyst reports show a mix of ratings, including buys, holds, and a "strong sell." The company's stock performance indicates a current price of $11.82, a market cap of $1.03 billion, and institutional investors holding 91.78% of its stock.
BlackRock (OLMA holder) discloses 6.24M Olema Pharmaceuticals shares in 13G/A
BlackRock, Inc. has filed an amended Schedule 13G/A disclosing beneficial ownership of 6,244,212 shares of Olema Pharmaceuticals, Inc. common stock, representing 7.1% of the outstanding class as of June 30, 2026. BlackRock reported sole voting power over 6,138,842 shares and sole dispositive power over all 6,244,212 shares. The filing indicates that no single person among the underlying clients or investors holds more than five percent of Olema's outstanding common stock through these holdings.
Have Olema Pharmaceuticals Insiders Been Selling Stock?
Olema Pharmaceuticals has seen insider stock sales, with the Independent Director divesting US$291k worth of shares and the Chief Medical Officer selling US$3.6m worth of shares over the last year, though the latter was at a price higher than the current market value. No insider purchases have been made in the past year, and insider ownership stands at 2.7%. The analysis suggests caution due to the selling activity and modest insider ownership.
Olema Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:OLMA
This article provides a company profile for Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) on the TradingView platform. It outlines access to financial data, statements, statistics, and other fundamental information for the company. The page focuses on the revenue breakdown and overall financial performance accessible to users.
Insider Selling: Olema Pharmaceuticals (NASDAQ:OLMA) Director Sells 12,500 Shares of Stock
Olema Pharmaceuticals (NASDAQ:OLMA) Director Cyrus Harmon sold 12,500 shares of the company's stock for $144,750, reducing his ownership by 1.72%. The stock has recently traded down to $11.30, significantly below its 12-month high of $36.26, and the company reported a quarterly loss of $0.52 per share. Despite the sale and stock decline, analysts maintain a "Moderate Buy" rating with an average price target of $44.10.
Form 4 Olema Pharmaceuticals Inc For: 27 July By Investing.com
This article reports on a Form 4 filing for Olema Pharmaceuticals Inc. for transactions that occurred on July 27. It provides the title of the regulatory filing and indicates that more information can be found on Investing.com. The piece is brief, serving mainly as an announcement of the filing.
Olema Pharmaceuticals Inc (OLMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
Olema Pharmaceuticals Inc (OLMA) has not yet disclosed relevant data regarding its revenue breakdown by business segments or regional contributions. The article, provided by TradingKey, notes the company's current stock performance, market capitalization, and P/E TTM. It indicates that further revenue details are unavailable at this time.
Olema Pharmaceuticals director Cyrus Harmon sells $291k in stock
Olema Pharmaceuticals director Cyrus Harmon sold 25,000 shares of company stock for a total of $291,162 over two days in late July 2026. Following these sales, Harmon's direct ownership is 702,770 shares, with an additional 117,028 shares held indirectly. Despite recent analyst buy ratings and progress in clinical trials, the stock has experienced significant volatility and is considered overvalued by InvestingPro.
Olema Pharmaceuticals Inc (OLMA) Cash Flow
This article provides a detailed cash flow statement for Olema Pharmaceuticals Inc (OLMA), covering quarterly and annual operating, investing, and financing activities. It includes financial figures for net income, changes in working capital, capital expenditures, and free cash flow over several fiscal periods. The article also features an FAQ section explaining key cash flow concepts and their relevance to OLMA's financial performance.
Olema Pharmaceuticals Inc (OLMA) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of Olema Pharmaceuticals Inc (OLMA) shareholder structure, listing major shareholders and their proportional holdings as of updated dates. It also categorizes shareholders by type and presents institutional shareholding data over several quarters, including changes in shares held and proportion. Additionally, it lists ETFs with holdings in OLMA.
Olema Pharmaceuticals Inc (OLMA) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a detailed risk assessment for Olema Pharmaceuticals Inc (OLMA), focusing on volatility, financial risk, and investment risk metrics. It presents various performance indicators such as Beta, VaR, Maximum Drawdown, Volatility, and Sharpe Ratio across different timeframes alongside liquidity measures. The data aims to offer insights into OLMA's risk profile for potential investors.
Olema Pharmaceuticals (NASDAQ:OLMA) Downgraded by Wall Street Zen to "Strong Sell"
Wall Street Zen downgraded Olema Pharmaceuticals (NASDAQ:OLMA) to a "strong sell" from "sell," adding to mixed analyst opinions. Despite this, the overall analyst consensus remains a "Moderate Buy" with an average price target of $44.10, significantly above its current trading price of $11.70. The company, which is focused on its breast cancer drug pipeline, faces continued losses and trades below its 200-day moving average.
OLMA (NASDAQ: OLMA) insider plans Rule 144 sale of 12,500 common shares
Cyrus L. Harmon, an insider at Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), has filed a Rule 144 notice to sell 12,500 common shares through Fidelity for an indicated value of $146,419.49 on July 24, 2026. This filing also discloses a prior sale of 12,500 common shares on July 23, 2026, for $144,737.53, which were originally acquired as founders shares in 2007 as compensation. The SEC filing provides details on the planned sale and clarifies key financial terms and transactions.
Siren L.L.C. Boosts Stake in Olema Pharmaceuticals, Inc. $OLMA
Siren L.L.C. significantly increased its stake in Olema Pharmaceuticals (NASDAQ:OLMA) during the first quarter, adding 1.46 million shares to hold a total of 4.76 million shares valued at about $70.9 million. Other institutional investors like Goldman Sachs and Geode Capital also raised their positions, indicating continued interest. Despite the company still reporting losses and recent share prices around $11.74, analysts have a "Moderate Buy" consensus rating with an average target price of $44.10.
Olema Pharmaceuticals, Inc. SEC Filing (Jul 23, 2026)
This article reports on an SEC Form 144 filing by Olema Pharmaceuticals, Inc. (OLMA) on July 23, 2026. The filing indicates a proposed sale of 12,500 common shares by a person affiliated with the issuer, acquired in 2007 as founder's shares. The aggregate market value of these securities is stated as $144,737.53, with the sale to be conducted via Fidelity Brokerage Services LLC on NASDAQ.
339,461 Shares in Olema Pharmaceuticals, Inc. $OLMA Bought by SEB Asset Management AB
SEB Asset Management AB has acquired 339,461 shares of Olema Pharmaceuticals (NASDAQ:OLMA) in the first quarter, representing a stake worth approximately $5.06 million and about 0.39% of the company. Institutional investors collectively own 91.78% of GLMA, indicating strong interest despite mixed analyst ratings. The stock currently holds a "Moderate Buy" consensus rating with an average price target of $44.10.
Jennison Associates LLC Has $27.17 Million Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA
Jennison Associates LLC significantly increased its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 89.0% in the first quarter, now holding over 1.8 million shares valued at $27.17 million. This move is part of a broader trend of institutional investors and hedge funds acquiring substantial positions in the company, which collectively own 91.78% of its stock. Despite a "Moderate Buy" consensus from analysts, the stock has recently experienced a drop in price target from some firms, though many still maintain a "Buy" rating.
